Roche buys US group Anadys for $230 million
Swiss drugmaker Roche said Monday it has agreed to buy Anadys Pharmaceuticals for $230 million (166 million euros), a move which would give it access to hepatitis C treatments being developed by the US group.
Under the deal, Roche is offering to pay $3.70 per share in cash, a premium of 256 percent to the US group's October 14 closing price.
"This acquisition augments our already strong hepatitis C virus portfolio," said Jean-Jacques Garaud, who heads Roche's pharma research and development.
One drug currently developed by the San Diego based group is the anti-viral Setrobuvir, which is undergoing clinical trials.
© 2011 AFP